<DOC>
	<DOCNO>NCT00255190</DOCNO>
	<brief_summary>The purpose study determine long-term safety profile daily treatment dexlansoprazole MR subject gastroesophageal reflux disease .</brief_summary>
	<brief_title>Safety Quality Life Study Dexlansoprazole Modified Release Formulation Treat Heartburn</brief_title>
	<detailed_description>This open-label study intend determine long-term safety profile dexlansoprazole MR 12 month dose 60 mg once-daily ( QD ) 90 mg QD subject gastroesophageal reflux disease ( GERD ) , include esophageal erosion . Prior protocol amendment , 300 subject successfully complete one symptomatic nonerosive gastroesophageal reflux study T-GD04-082 ( NCT00251745 ) T-GD04-083 ( NCT00251758 ) randomly assign receive placebo dexlansoprazole MR 60 90 mg QD . Subjects enrol one symptomatic GERD study randomly assign 1:1 ratio receive either dexlansoprazole MR 60 90 mg QD long-term study . After implementation protocol amendment # 4 , additional 300 subject gastroesophageal reflux disease include erosive esophagitis enrol treated dexlansoprazole MR 90 mg QD 12 month . Approximately 200 study site U.S. participate . For analysis involve visit treatment subject enrol prior protocol amendment # 4 , baseline refers pretreatment Study T-GD04-082 ( NCT00251745 ) T-GD04-083 ( NCT00251758 ) . For subject enrol protocol amendment # 4 , baseline base screen predosing measurement .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<criteria>Subjects must successfully complete either TGD04082 ( NCT00251745 ) TGD04083 ( NCT00251758 ) diagnosis gastroesophageal reflux disease without erosive esophagitis . Any condition may require inpatient surgery course study . Use prescription nonprescription proton pump inhibitor , histamine ( H2 ) receptor antagonist , sucralfate , misoprostol prokinetics throughout study . Use antacids [ except study supply GelusilÂ® ] . Subjects use drug significant anticholinergic effect tricyclic stay stable dose 4 week prior dose throughout study . Evidence uncontrolled systemic disease . Allergy proton pump inhibitor include Prilosec , Nexium , Prevacid , others , component dexlansoprazole MR , Gelusil/antacid . Need take blood thinner . Need take 12 dos nonsteroidal antiinflammatory drug per month . Had cancer ( except basal cell cancer skin ) within 3 year prior screen . Has esophageal disease include Barrett 's esophagus strictures require dilation . Has radiation cryotherapy esophagus . Has active gastric duodenal ulcer within 4 week start study drug . Has history hypersecretory condition Zollinger Ellison Syndrome . History alcohol abuse . Has acquire immunodeficiency syndrome . Has acute upper gastrointestinal bleeding within 4 week endoscopy . Received blood product transfusion within 3 month take first dose study drug . Has previously participate another dexlansoprazole MR longterm treatment clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Gastroesophageal Reflux Disease</keyword>
</DOC>